Related Experiment Videos
Structures of enzymatically modified products of arbekacin by methicillin-resistant. Staphylococcus aureus
Abstract:
Only a limited number of strains of methicillin-resistant Staphylococcus aureus (MRSA) moderately resistant to arbekacin (ABK) have been isolated clinically. Three inactivated products of ABK have been obtained by reaction with excess amounts of a crude enzyme preparation extracted from an ABK-resistant MRSA strain (MIC, 25 micrograms/ml). The 2"-O-phosphate was the major product together with small amounts of the 6'-N-acetate and the double modification product. The structures of these modification products were determined by MS and NMR spectral analyses.
Insights
Researchers identified how methicillin-resistant Staphylococcus aureus (MRSA) inactivates arbekacin (ABK). Enzymes from resistant MRSA produced 2"-O-phosphate and 6'-N-acetate modification products, explaining ABK resistance.
Area of Science:
- Microbiology
- Biochemistry
- Drug Resistance
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant clinical challenge.
- Limited understanding exists regarding the mechanisms of arbekacin (ABK) resistance in MRSA strains.
- Arbekacin is a crucial antibiotic for treating resistant bacterial infections.
Purpose of the Study:
- To investigate the enzymatic inactivation of arbekacin (ABK) by a moderately resistant MRSA strain.
- To identify and characterize the products resulting from ABK modification by MRSA enzymes.
Main Methods:
- Cultivation of a clinically isolated, arbekacin-resistant MRSA strain (MIC: 25 µg/mL).
- Preparation of a crude enzyme extract from the resistant MRSA strain.
- Incubation of arbekacin with the enzyme extract to observe inactivation.
- Structural elucidation of modification products using Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR) spectral analyses.
Main Results:
- Three inactivated products of arbekacin were identified.
- The major product was determined to be 2"-O-phosphate.
- Minor products included 6 -N-acetate and a double modification product.
Conclusions:
- Enzymatic modification is a key mechanism for arbekacin resistance in this MRSA strain.
- The identified 2"-O-phosphate and 6 -N-acetate products contribute to arbekacin inactivation.
- Understanding these resistance mechanisms is vital for developing strategies against MRSA infections.